Santarus, Inc.
Santarus, Inc., a prominent biopharmaceutical company headquartered in the United States, has established itself as a leader in the development of innovative therapies for gastrointestinal and rare diseases. Founded in 2003, Santarus has achieved significant milestones, including the successful launch of several FDA-approved products that address unmet medical needs.
The company focuses on specialised areas such as inflammatory bowel disease and other gastrointestinal disorders, offering unique formulations that enhance patient compliance and treatment outcomes. Santarus is recognised for its commitment to research and development, positioning itself strongly within the biopharmaceutical industry. With a robust portfolio of core products, Santarus continues to make strides in improving the quality of life for patients worldwide.
-11 vs industry average
Santarus, Inc.’s score of 27 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Santarus, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Santarus, Inc. yet.
Santarus, Inc.'s reported carbon emissions
Santarus, Inc., headquartered in the US, currently does not report specific carbon emissions data, as there are no available figures for emissions in kg CO2e. The company is a current subsidiary of Bausch Health Companies Inc., which may influence its climate commitments and reporting practices.
While Santarus, Inc. does not have its own documented reduction targets, it inherits climate initiatives from its parent company, Bausch Health Companies Inc. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). These initiatives aim to align corporate strategies with climate science and enhance transparency regarding environmental impact.
As a subsidiary, Santarus may benefit from Bausch Health's broader sustainability goals, although specific targets or achievements at the Santarus level remain unspecified. The absence of direct emissions data highlights the need for further clarity on the company's individual climate commitments and performance.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Santarus, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Santarus, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Bausch Health Companies Inc.
Carbon Disclosure Project
Inherited from Bausch Health Companies Inc.
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Santarus, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project